Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/25336
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSánchez-Ramón, Silvia
dc.contributor.authorDhalla, Fatima
dc.contributor.authorChapel, Helen
dc.date.accessioned2019-06-28T14:32:35Z-
dc.date.available2019-06-28T14:32:35Z-
dc.date.issued2016
dc.identifier.citationFront Immunol.2016;(7):317
dc.identifier.issn1664-3224
dc.identifier.urihttps://hdl.handle.net/20.500.12530/25336-
dc.description.abstractPatients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are prone to present with antibody production deficits associated with recurrent or severe bacterial infections that might benefit from human immunoglobulin (Ig) (IVIg/SCIg) replacement therapy. However, the original IVIg trial data were done before modern therapies were available, and the current indications do not take into account the shift in the immune situation of current treatment combinations and changes in the spectrum of infections. Besides, patients affected by other B cell malignancies present with similar immunodeficiency and manifestations while they are not covered by the current IVIg indications. A potential beneficial strategy could be to vaccinate patients at monoclonal B lymphocytosis and monoclonal gammopathy of undetermined significance stages (for CLL and MM, respectively) or at B-cell malignancy diagnosis, when better antibody responses are attained. We have to re-emphasize the need for assessing and monitoring specific antibody responses; these are warranted to select adequately those patients for whom early intervention with prophylactic anti-infective therapy and/or IVIg is preferred. This review provides an overview of the current scenario, with a focus on prevention of infection in patients with hematological malignancies and the role of Ig replacement therapy.
dc.language.isoeng
dc.rightsopenAccess-
dc.subjectantibody production defect
dc.subjectchronic lymphocytic leukemia
dc.subjecthematological malignancy
dc.subjecthypogammaglobulinemia
dc.subjectmultiple myeloma
dc.subjectreplacement immunoglobulins
dc.titleChallenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy.
dc.typeArtículo
dc.identifier.pubmedID27597852
dc.format.volume7
dc.format.page317
dc.identifier.journalFrontiers in immunology
dc.identifier.doi10.3389/fimmu.2016.00317
dc.identifier.pmcPMC4993076
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. Clínico San Carlos > Artículos

Files in This Item:
File Description SizeFormat 
PMC4993076.pdf203.55 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.